Biocon Limited

rs,

5, 2022 To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/Madam, Subject: Investor Presentati

Rs. 8,397

T E D B I O C O N L I M I T E D 5 5 Biocon Today: Strategically poised for a strong global play Rs. 8,397 Cr | $1.1bn Revenue* ~15,000 Total Employees* ~1,300 Patents* 120+ Countries where our products

13%

o Top 5 among global pharma & biotech employer since 2012 o Published Human Rights Policy o 13% revenue in gross R&D spend (Ex Syngene) o Recognized by UN Women for efforts to promote divers

Rs. 11 Crore

o Recognized by UN Women for efforts to promote diversity o 13% increase in women in workforce o Rs. 11 Crore in CSR Spend o 120+ students graduated from Biocon Academy o 58% electricity came from green po

58%

women in workforce o Rs. 11 Crore in CSR Spend o 120+ students graduated from Biocon Academy o 58% electricity came from green power o 100% waste water recycled & reused o 118K tCO2 GHG offset

100%

Spend o 120+ students graduated from Biocon Academy o 58% electricity came from green power o 100% waste water recycled & reused o 118K tCO2 GHG offset o Board Committees, policies for global

rs 75

itical intermediates ~$65b Global Generic API Market Size 2022E* 40+ APIs 700+ API customers 75+ Countries served by API across US, Europe & large emerging markets 5 Facilities in India *

₹623

rowth both in API & generic formulations Sitagliptin and Vildagliptin API launches in EU Revenue ₹623Cr ₹530Cr +18% Generic Formulations - Approvals in EU & MoW markets to aid geographical expansio

₹530

th in API & generic formulations Sitagliptin and Vildagliptin API launches in EU Revenue ₹623Cr ₹530Cr +18% Generic Formulations - Approvals in EU & MoW markets to aid geographical expansion Vizag

18%

& generic formulations Sitagliptin and Vildagliptin API launches in EU Revenue ₹623Cr ₹530Cr +18% Generic Formulations - Approvals in EU & MoW markets to aid geographical expansion Vizag immunos

₹54

ilities – Process validation batches are scheduled to commence in Q3 FY23 Profit Before Tax (PBT) ₹54Cr ₹50Cr +9% 9% of revenue 9% of revenue Classified as Public B I O C O N L I M I T E D B I O

₹50

– Process validation batches are scheduled to commence in Q3 FY23 Profit Before Tax (PBT) ₹54Cr ₹50Cr +9% 9% of revenue 9% of revenue Classified as Public B I O C O N L I M I T E D B I O C O N L

Entering adjacencies in communicable disease

1

Adjusted for

1

Entering adjacencies in communicable disease

infectious disease antibodies and vaccines Key Commercial Products (COVID -19) Recent Collaborations 50,000+ lives impacted Continued portfolio expansion Classified as Public B I O C O N L I M I T E D B I O C O N L I M I T E D B I O C O N L I M I T E D 19 19 Asset-light entry into vaccines through SILS alliance 1 2 3 B B L R I G H T S Access to 100m doses of vaccines annually for ~15 years Commercialization rights of the SILS portfolio for global markets BBL to have committed revenue stream and related margins from H2 FY23 Alliance to commercialize SILS COVID portfolio and other next generation vaccines Note: Transaction subject to completion of the acquisition of Covishield Technologies Private Limited (CTPL); Classified as Public B I O C O N L I M I T E D B I O C O N L I M I T E D B I O C O N L I M I T E D 20 20 Comprehensive portfolio of 20 biosimilars and vaccines… Therapeutic Area Molecule US Dev. Markets: ex-US MoW4 Commentary B I O S I M I L A R P R O D U C T S T A T U S Oncolog

Adjusted for

Dilution gain in Bicara of ₹33 Cr in Q2 FY23 MTM gain on investments ₹55 Cr Q2 FY22 Gross R&D spend at ₹252 Cr, up ₹86 Cr R&D spend in P&L ₹242 Cr, up ₹96 Cr Forex Loss of ₹82 Cr vs gain of ₹20 Cr in Q2 FY22 * Core EBITDA defined as EBITDA before forex, dilution gain in Bicara, R&D, licensing income and mark to market gain on investments Classified as Public B I O C O N L I M I T E D B I O C O N L I M I T E D B I O C O N L I M I T E D 30 30 Financial Highlights: Q2 FY23 (2/2) Net Profit (before exceptional charge) ₹168 Cr ₹188 Cr Exceptional Items ₹122 Cr ₹50 Cr Exceptional items during Q2 FY23: MAT credit balance charge of ₹107 Cr on adoption of new tax regime of 25%. This move helps Biocon reduce tax outflow and P&L charge on a go-forward basis. Professional fees, net of tax of ₹14 Cr towards the Viatris deal Net Profit (Reported) ₹47 Cr ₹138 Cr In Q2 FY22, exceptional items net of tax and minority were ₹50 Cr Classified as Public B I O C O N L I M I T E D B I O C O N L I M I T E D B